[ad_1]
ABCVAC (Brazilian Association of Vaccine Clinics) said on Sunday (January 3, 2021) that it is negotiating the purchase of 5 million doses of the Covaxin vaccine, developed in India by the Bharat Biotech laboratory.
The immunizer had its emergency use authorized by India this Sunday, and is in the third phase of testing. It will need the approval of Anvisa (National Health Surveillance Agency) to be used in Brazil.
The vaccine has not yet revealed its effectiveness. The immunizer is made of coronavirus particles that have died, rendering them unable to infect or replicate. 2 doses are required in the application, and its conservation is between 2 to 8º C.
The Indian government also approved the vaccine developed by AstraZeneca and the University of Oxford, which is named after Covishield in the country. Its efficacy is 70.4%, also requiring a 2nd dose in the vaccination process.
ABCVAC president Geraldo Barbosa said that the immunizer was offered to the federal government and that the company made a surplus available to private clinics.
He is traveling to India this week (January 4-8, 2021) with a government delegation to learn about the industry and assess whether Bharat Biotech can supply the negotiated quantity. “The idea is to know if this capacity really exists and if it will not generate a frustrated expectation in the future.”
Barbosa said he signed a memorandum of intention to buy for 5 million initial doses, a capacity offered by the company. The president of ABCVAC said that “He’s fighting” to increase the quantity.
“What we have seen so far with all the treatments is that yes, we will have a vaccine available in the private market in 2021.”, He told the News this Sunday. He stressed that when he is certain that the negotiation is concluded, he will take care of finding enough syringes and needles to serve the market.
OR Power360 revealed in December that the vaccines could also be applied by hospitals and private clinics, as soon as they obtain authorization for their use in the public system by Anvisa.
keep reading
[ad_2]
